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Abstract
Background: Excessive osteoclast activity, which is strongly stimulated by pro-inflammatory mediators, results in
bone and cartilage degeneration as central features of many arthritides. Levels of the alarmin S100A8/A9 and
interleukin (IL)-1β are both increased in arthritis patients and correlate with disease activity and progression of
tissue erosion. We previously presented S100A8/A9 as a good biomarker for joint inflammation and arthritis
pathology under circumstances of high IL-1 signaling in mice that lack the gene encoding IL-1 receptor antagonist
(Il1rn−/− mice). Here, we investigated whether S100A8/A9 is also actively involved in the development of joint
inflammation and both cartilage and bone pathology under these conditions by comparing Il1rn−/− mice with mice
that have an additional deficiency for S100a9 (Il1rn−/−XS100a9−/−).
Methods: Il1rn−/−XS100a9−/− on a BALB/c background were obtained by crossing S100a9−/− mice and Il1rn−/− mice.
Arthritis incidence and severity were macroscopically scored. Myeloid cell populations in the bone marrow and
spleen were determined using flow cytometry. In vitro osteoclastogenesis of bone marrow cells was evaluated with
TRAP staining. Microscopic joint inflammation, cartilage degeneration, and bone destruction were evaluated using
histology of ankle joints of 12- and 20-week-old mice.
Results: Macroscopically scored arthritis severity was comparable between Il1rn−/− and Il1rn−/−XS100a9−/− mice.
Inflammation, cartilage erosion, and bone erosion were clearly present in 12-week-old mice of both strains lacking
Il1rn−/−, but not significantly different between Il1rn−/−XS100a9−/− and Il1rn−/−. Moreover, we observed that the
numbers of neutrophils and monocytes were increased by the absence of Il1rn, which was affected by the absence
of S100a9 only in the spleen but not in the bone marrow. In line with our other findings, the absence of S100a9
did not affect the osteoclastogenic potential of osteoclast precursors in the absence of Il1rn. Finally, in agreement
with the findings in early arthritis development in 12-week-old mice, cartilage and bone erosion in 20-week-old
mice was significantly higher in both Il1rn−/− strains, but the additional absence of S100a9 did not further affect
tissue pathology.
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Conclusion: S100A8/A9 deficiency does not significantly affect inflammation and joint destruction in mice with
high IL1β signaling suggesting that S100A8/A9 is not essential for the development of arthritis under these
conditions.
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Introduction
Arthritides form a large and heterogeneous group of dis-
eases and predominantly affect articular joints. Erosion
of the articular cartilage and of the peri-articular bone
are central features in most of these diseases and are
mediated by osteoclasts, multinucleated cells that differ-
entiate from myeloid precursors under the influence of
macrophage colony-stimulating factor (M-CSF) and re-
ceptor activator of nuclear factor kappa-Β ligand
(RANKL) [1, 2]. During steady-state conditions, balanced
bone resorption by osteoclasts and bone formation by
osteoblasts ensure homeostatic bone turnover and re-
modeling. Under arthritic conditions, however, the ex-
cess of immune cells present in the synovium of affected
joints produce a plethora of damage-associated molecu-
lar patterns (DAMPs), also referred to as alarmins, and
pro-inflammatory factors that strongly promote the dif-
ferentiation and resorptive activity of osteoclasts, leading
to excessive bone erosion [3–6].
Two key factors that are highly produced under arth-
ritic conditions are the alarmin S100A8/A9 and interleu-
kin (IL)-1β. Elevated levels of S100A8/A9 can be
measured in the synovium, synovial fluid, and serum
during various rheumatic diseases, and these levels cor-
relate with disease activity and radiographic progression,
suggesting its involvement in pathology [7–17]. More
specifically, we have previously shown that S100A8/A9
promotes osteoclast-mediated bone resorption [6]. This
alarmin is present in the cytoplasm of myeloid cells, but
upon cell stress as the result of e.g. inflammation or tis-
sue damage, S100A8/A9 is secreted whereupon it rapidly
activates the immune system, predominantly via binding
to Toll-like receptor 4 [18–20]. High IL-1 signaling has
been found in several types of seronegative arthritis and
is most pronounced in systemic onset juvenile idiopathic
arthritis [21–23]. IL-1β can bind to the type 1 IL-1 re-
ceptor (IL-1RI) or the non-signaling type 2 IL-1 receptor
(IL-1RII). The IL-1 receptor antagonist (IL-1RA) com-
petitively blocks the binding of IL-1β to IL-1RI and
thereby decreases IL-1 signaling [24]. Mice that are defi-
cient in the gene encoding IL-1RA (Il1rn−/− mice) there-
fore represent an ideal model to study high IL-1
signaling. These mice spontaneously develop non-
immune complex-mediated joint pathology which in-
cludes severe joint inflammation, cartilage destruction,
and bone erosion that is associated with marked osteo-
clast activity [25].
A previous study from our group showed that the
serum levels of S100A8/A9 were a potent biomarker for
joint inflammation and destruction in these Il1rn−/−
mice. Serum levels of S100A8/A9 were markedly in-
creased in these mice compared to wild type controls
and strongly correlated with various disease parameters,
such as macroscopic arthritis severity and histologically
scored inflammation, bone erosion, chondrocyte death,
proteoglycan depletion, and (PG) cartilage erosion.
Moreover, we demonstrated that serum S100A8/A9
levels early after disease onset were prognostic for the
disease outcome [26]. Therefore, in the present study,
we investigated the functional role of S100A8/A9 in the
development of joint inflammation and destruction of
cartilage and bone under conditions of high IL-1 signal-
ing. Hereto, we generated Il1rn−/−XS100a9−/− double
knockout mice and compared various joint pathology
parameters between these double knockout and Il1rn−/−
mice, whereas S100a9−/− and wild type (WT) mice were
used as control. Moreover, we investigated various im-
mune cell subsets in the bone marrow and spleen of
these mice and compared the osteoclastogenic potential
of osteoclast precursors between the various strains.
Materials and methods
Mice
Il1rn−/−XS100a9−/− on a BALB/c background were ob-
tained by crossing S100a9−/− mice (own facilities) and
Il1rn−/− (previously kindly provided by Dr. M. Nicklin,
The University of Sheffield, Sheffield, UK) [27]. Single
knockout Il1rn−/− and S100a9−/− control strains were
then generated by crossing the heterozygous
Il1rn+/−XS100a9+/−. BALB/c wild type (WT) controls
were purchased from Envigo. Development of arthritis
in the ankle and paws was macroscopically scored on a
scale from 0 to 2 per paw (0, no redness and swelling;
0.25, slight redness; 0.5, slight redness and swelling;
0.75–1, mild redness and swelling; 1.25–1.5, moderate
redness and swelling; 1.75–2, severe redness and swell-
ing) and the arthritis severity is presented as the area
under the curve (AUC). Mice were sacrificed at the age
of 12 weeks or 20 weeks old. Mice were housed under
standard housing conditions: filter top cages, 12 h light-
dark cycle, and ad libitum access to animal chow and
water. All experiments involving animals were con-
ducted according to the Dutch law and approved by the
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Dutch Central Authority for Scientific Procedures on
Animals (#AVD103002015115).
Histological analysis
Total ankle joints were isolated from 12- and 20-week-
old mice, fixed in 4% phosphate-buffered formalin at
room temperature, decalcified in 10% ethylenediamine-
tetraacetic acid (EDTA) at 4°C for 2 weeks, embedded in
paraffin, and 7-μm coronal sections were prepared,
representing the entire depth of the joint. Sections were
stained with hematoxylin and eosin and Safranin-O and
Fast Green for histological analysis. Inflammation of the
entire ankle joint was arbitrarily scored on a scale from
0 (no inflammation) to 3 (severe inflammation). Bone
destruction was evaluated in 8 well-defined areas along
the tibia, talus, and navicular with a score ranging from
0 (no erosion) to 3 (connection between the joint cavity
and bone marrow or more extensive bone destruction).
Degeneration of the articular cartilage layers at the tibia,
talus, and navicular bone were scored on a scale from 0
(no erosion) to 3 (complete erosion of the calcified car-
tilage layer). Proteoglycan depletion in the articular car-
tilage was evaluated in the same four locations as
cartilage erosion and scored on a scale from 0 (no PG
depletion) to 3 (complete PG depletion). A total of 3
sections per joint from various depths were scored and
results from all locations were averaged (Additional file
1).
Flow cytometric analysis
Total bone marrow cells from femurs of 12-week-old
mice were isolated by crushing the femurs of mice with
mortar and pestle in medium and passing the cell sus-
pension through a 70-μm nylon cell strainer. Total cell
populations of whole spleen cells were isolated by mash-
ing the spleen over a 70-μm nylon cell strainer. After
lysis of erythrocytes in lysis buffer (155 mM NH4Cl 12
mM KHCO3 0,1 mM EDTA pH 7.3), cells were counted
and subsequently incubated with Fc-blocking antibody
(BD Pharmingen anti-mouse CD16/CD32, BD Biosci-
ences). Cells were then stained with the following mix of
antibodies: CD11b-fluorescein isothiocyanate (FITC),
CD3-phycoerythrin (PE), Ter-119-PE, CD45R/B220-PE,
CD49b-PE, NK1.1-PE, Ly6G-allophycocyanin (APC),
Ly6C-allophycocyanin-cyanine 7 (APC-Cy7), and an
eFluor450 fixable viability dye. Samples were acquired
with a Gallios flow cytometer (Beckman Coulter Life
Sciences) and data analysis was performed with Kaluza
Analysis Software 2.1 (Beckman Coulter Life Sciences).
The gating strategy is shown in Additional file 2.
Bone marrow-derived osteoclast differentiation
Total bone marrow cells were isolated from the femurs
of 12-week-old mice and were seeded in Petri dishes at a
density of 106 cells/mL in 10 mL of α-minimum essen-
tial medium (αMEM) (Thermo Fisher Scientific), supple-
mented with 10% fetal calf serum (FCS), 100 U/mL
penicillin, and 100 μg/mL streptomycin in the presence
of 30 ng/mL recombinant mouse (rm)M-CSF (R&D Sys-
tems). At day 3 of culture, cells were trypsinized and
seeded in 96-well plates at a density of 25 × 104 cells/
well in αMEM supplemented with 30 ng/mL of rmM-
CSF and 20 ng/mL rmRANKL (R&D Systems). The cul-
ture medium was refreshed after 3 days. After 4 days of
differentiation in the presence of RANKL, cells were
fixed with 4% PFA and stained for tartrate-resistant acid
phosphatase (TRAP), using the Leukocyte Acid Phos-
phatase Kit (Sigma-Aldrich) according to the manufac-
turer’s protocol. Cells with three or more nuclei were
considered osteoclasts and were further scored as small
osteoclasts with 3–5 nuclei and bigger osteoclasts with
≥6 nuclei.
Statistical analysis
Statistical differences between multiple groups were cal-
culated using a Kruskal-Wallis test followed by Dunn’s
multiple comparison test. A two-way ANOVA was per-
formed to study the effects of Il1rn and S100a9 deficien-
cies and their interaction. Statistical differences between
two groups were tested using a Mann-Whitney test.
Correlation between parameters was determined by cal-
culating Spearman’s rank correlation coefficients. All
analyses were performed using Graph Pad Prism 5.03
(Graph Pad Software) and P-values less than 0.05 were
considered significant.
Results
The absence of S100a9 does not affect arthritis severity in
Il1rn−/− mice during early arthritis
First, we determined whether, in line with previous ob-
servations from our lab, serum S100A8/A9 levels corre-
lated with histologic inflammation in Il1rn−/− mice and
we confirmed a strong correlation in the present set of
mice (Additional file 3A). Next, we investigated whether
differences in the incidence and macroscopic severity of
arthritis could be observed between 12-week-old Il1rn−/−
and Il1rn−/− mice that additionally lacked S100a9. We
observed a slightly increased disease incidence in
Il1rn−/−XS100a9−/− as compared to Il1rn−/− mice (Fig. 1A).
However, the course of arthritis severity development in
the positive mice unexpectedly showed no significant differ-
ences between the two strains in the cumulative score, rep-
resented by the area under the curve (Fig. 1B). As expected,
S100a9−/− and WT controls did not develop any macro-
scopically visible arthritis. In agreement with these findings,
microscopic scoring of tissue sections for inflammation in
the ankle joints showed that the strains that were deficient
in Il1rn developed significantly more inflammation
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compared to the S100a9−/− and WT controls, whereas no
significant differences could be observed between
Il1rn−/−XS100a9−/− and Il1rn−/− mice (Fig. 1C).
S100A8/A9 is not functionally involved in cartilage and
bone erosion in Il1rn−/− mice during early arthritis
Next, we determined whether the absence of S100a9 af-
fected cartilage degeneration and bone erosion in 12-
week-old mice. Again in agreement with our previous
observations, serum S100A8/A9 levels in the Il1rn−/−
mice used here strongly correlated with both cartilage
and bone erosion (Additional file 3B and 3C). As pre-
sented in Fig. 2A and B, WT and S100a9−/− mice hardly
had any degeneration of the articular cartilage or bone
erosion, whereas Il1rn−/− and Il1rn−/−XS100a9−/− mice
showed severe pathology. Quantification showed that
both cartilage erosion (Fig. 2C) and bone erosion (Fig.
2D) were significantly higher in both strains lacking
Il1rn−/− as compared to mice that were sufficient in
Il1rn. In the strains deficient in Il1rn, the number of
mice with severe pathology seemed highest in the
Il1rn−/−XS100a9−/− group, where particularly the distal
Fig. 1 The absence of s100a9 does not affect inflammation in the ankle joints of Il1rn−/− mice. Arthritis incidence, based on the macroscopic
score of the ankle joints, was increased in Il1rn−/−XS100a9−/− compared to Il1rn−/− mice (A). However, the severity of arthritis in the positive mice
was comparable (B). Representative photomicrographs of hematoxylin and eosin-stained sections showing examples of inflammation in the ankle
joints of 12-week-old wild type (WT), S100a9−/−, Il1rn−/−, and Il1rn−/−XS100a9−/− mice (C, original magnification ×50). Quantification of the degree
of inflammation of the ankle joints using an arbitrary score showed that the strains deficient in Il1rn developed significantly more inflammation
compared to the S100a9−/− and WT controls. However, no significant differences in inflammation were observed between Il1rn−/−XS100a9−/− and
Il1rn−/− mice. Line graphs are shown, representing the percentage of positive mice in A and mean ± SEM values of arthritis severity in B.
Scatterplots are shown, with horizontal and vertical lines representing mean ± SEM values (C). Each data point represents the sum score of the
right and left ankle joint of one mouse. ns not significant, ***P < 0.001. Results of the two-way ANOVA with interaction are presented in the table
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Fig. 2 The absence of S100A9 does not ameliorate cartilage and bone erosion in 12-week-old Il1rn−/− mice. Representative photomicrographs of
Safranin-O/Fast Green-stained sections showing cartilage and bone erosion in the ankle joints of wild type, S100a9−/−, Il1rn−/−, and
Il1rn−/−XS100a9−/− mice (A, original magnification ×200 and B, original magnification ×100). Quantification of cartilage erosion at the tibia,
proximal and distal sides of the talus, and proximal side of the navicular bone with an arbitrary score showed increased cartilage erosion in Il1rn-
deficient strains compared to wild type and S100a9−/− mice. However, no significant differences were observed between Il1rn−/−XS100a9−/− and
Il1rn−/− mice (C). Additionally, quantification of bone erosion at 8 locations along the tibia, talus, and navicular bones with an arbitrary score
showed increased bone erosion in Il1rn-deficient strains compared to wild type and S100a9−/− mice while no significant differences were
observed between Il1rn−/−XS100a9−/− and Il1rn−/− mice (D). Scatterplots are shown, with horizontal and vertical lines representing mean ± SEM
values. Each data point represents the sum score of the right and left ankle joints of one mouse. ns not significant, **P < 0.01, ***P < 0.001. Results
of the two-way ANOVA with interaction are presented in the table
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part of the talus and the navicular bone (data not
shown) showed severe erosions of both bone and cartil-
age. However, for both parameters, this did not result in
a significant increase compared to Il1rn−/− mice.
S100A8/A9 levels affect the composition of myeloid cell
populations in the spleen but not in the bone marrow of
Il1rn−/− mice
In the next set of experiments, we set out to determine
whether the absence of S100a9 in Il1rn−/− mice affected
the composition of various myeloid cell populations in
the bone marrow and spleen. These cells are progenitors
of among others osteoclasts, which are key cells in the
erosion of bone and cartilage in these mice. Total cell
counts in the bone marrow were significantly higher in
mice that were deficient in Il1rn compared to the con-
trol strains, but not different between Il1rn−/− and
Il1rn−/−XS100a9−/− mice (Fig. 3A). Next, we determined
the number of CD11b+Ly6Ghigh neutrophils, pro-
inflammatory CD11b+Ly6G−Ly6Chigh monocytes and the
more immunomodulatory CD11b+Ly6G−Ly6Clow mono-
cytes, and CD11bneg/lowLy6Chigh osteoclast progenitors.
Cell numbers in all these populations were significantly
increased in the absence of Il1rn. Although a trend to-
wards increased numbers of neutrophils, Ly6Chigh
monocytes, and CD11bneg/lowLy6Chigh osteoclast progen-
itors and a negative trend for Ly6Clow monocytes could
be observed in the Il1rn−/−XS100a9−/− mice compared
to Il1rn−/− mice, this did not reach significance for any
of these populations.
In contrast to the bone marrow, total cell numbers in
the spleen were unchanged in Il1rn-deficient mouse
strains (Fig. 3B). Moreover, we observed an interaction
effect between the absence of Il1rn and S100a9 for the
numbers of neutrophils and Ly6Chigh but not for the
Ly6Clow monocytes, which was most likely the result of
increased numbers of these cells in the
Il1rn−/−XS100a9−/− mice.
Il1rn−/−XS100a9−/− and Il1rn−/− progenitor cells have a
comparable osteoclastogenic potential in vitro
Since osteoclasts are crucial for the bone and cartilage
destruction in this experimental arthritis model, we in-
vestigated the osteoclastogenic potential of bone marrow
cells obtained from all four mouse strains. To adjust for
the numbers of osteoclast precursors, we first seeded
total bone marrow cells on Petri dishes, stimulated these
with GM-CSF, and transferred comparable cell numbers
of all strains for the final osteoclast differentiation with
RANKL. Bone marrow cells of all strains gave rise to
TRAP-positive multinucleated osteoclasts (Fig. 4A).
Quantification of the generated osteoclasts showed no
major differences in the osteoclastogenic potential of the
cells with the four genotypes. Whereas cells from both
strains lacking Il1rn had more formation of larger osteo-
clasts (6 nuclei or more) as compared to cells obtained
from WT and S100a9−/− mice, no significant difference
could be observed between Il1rn−/−XS100a9−/− and
Il1rn−/− cells (Fig. 4B).
The absence of S100A8/A9 does not affect cartilage
proteoglycan depletion, cartilage erosion, and bone
erosion in ankle joints of Il-1rn−/− during late arthritis
Overall, although not significantly increased, 12-week-
old Il1rn−/−XS100a9−/− mice consistently showed a
trend towards increased bone and cartilage erosion and
showed increased numbers of pro-inflammatory
Ly6Chigh cells in the bone marrow and spleen. Therefore,
we investigated whether joint pathology was affected by
the absence of S100A8/A9 in Il1rn−/− mice later after
the onset of arthritis in 20-week-old mice. Severe cartil-
age and bone erosion were observed in the ankle joints
of both Il1rn−/− and Il1rn−/−XS100a9−/− mice (Fig. 5A,
B). Quantification of cartilage and bone erosion con-
firmed a strong increase in joint damage in
Il1rn−/−XS100a9−/− compared to S100a9−/− mice. Most
severe cartilage and bone erosions were observed in the
Il1rn−/−XS100a9−/− mice in the distal parts of the talus
and navicular bone, which we observed in 12-week-old
mice as well but was more profound in this set of 20-
week-old mice, although this did not result in a signifi-
cantly higher average score as compared to Il1rn−/− mice
(Fig. 5C, D).
Additionally, although scoring of cartilage proteogly-
can depletion might be strongly influenced by the pres-
ence of severe cartilage erosion, PG depletion was
increased in Il1rn−/−XS100a9−/− compared to S100a9−/−
mice. However, no differences were found between
Il1rn−/− and Il1rn−/−XS100a9−/− mice (Additional file 4).
Discussion
In the present study, we show that the absence of
S100a9 does not alter joint inflammation, cartilage de-
struction, and bone erosion in the ankle joints of Il1rn−/−
mice, suggesting that S100A8/A9 is not essential for the
development of arthritis in the presence of such exces-
sive IL-1 signaling.
We previously described that both local and serum
levels of S100A8/A9 are strongly elevated in Il1rn−/−
mice with high IL-1 signaling and that these levels
strongly correlated with inflammation and destruction
parameters. Moreover, serum S100A8/A9 levels at a
relatively early disease stage showed prognostic value for
the development of inflammation later on. Together,
these data show that S100A8/A9 may be crucially in-
volved in the development of inflammation and path-
ology under these conditions of high IL-1 signaling [26].
Therefore, in the present study, we set out to investigate
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this possible involvement. However, we observed that
the functional involvement of S100A8/A9 was very lim-
ited and not essential for the development of joint in-
flammation and destruction under these circumstances.
High levels of both the alarmin S100A8/A9 and the
pro-inflammatory cytokine IL-1β are found in many pa-
tients suffering from various forms of arthritis. The in-
volvement of these factors in the development of joint
pathology has previously been demonstrated in other ex-
perimental models of RA. These studies showed that the
absence of S100A8/A9 inhibited the development of
joint pathology in antigen-induced arthritis (AIA),
whereas the development of other models of experimen-
tal arthritis like the K/BxN serum transfer arthritis
model and collagen-induced arthritis (CIA) was not af-
fected, suggesting that the importance of S100A8/A9 is
model-dependent [6, 28, 29]. On the other hand,
whereas IL-1β was shown to be important for the devel-
opment of CIA and K/BxN serum transfer arthritis [30–
32], blocking this pro-inflammatory cytokine during AIA
did not decrease the inflammation in this model [33].
Together, these data show that the dependency of the
experimental arthritis models on S100A8/A9 or IL-1β is
model-specific, which might be due to factors like the
use of distinct triggers, local versus systemic inflamma-
tion, and variations in the predominant inflammatory
cell types that are involved in the development of disease
pathology in these models.
Normally, S100A8 and S100A9 monomers quickly
form heterodimers in the cell. Once released upon cell
stress, these heterodimers can activate the immune sys-
tem predominantly via Toll-like receptor 4 (TLR4) and
relatively quickly tetramerize under high calcium condi-
tions, such as present in the extracellular environment,
and therewith lose their capacity to activate the immune
system in a TLR4-dependent manner. Genetic ablation
of S100a9 in mice does not only result in the loss of
S100A9 expression, but also of functional S100A8 pro-
tein in the periphery because of the rapid degradation of
the S100A8 monomers by the proteasome, although pro-
tein expression can be observed in the bone marrow of
these mice [34, 35]. A recent study investigated the role
of S100A8/A9 under conditions of high tumor necrosis
factor α (TNFα), using mice deficient in tristetraprolin
(Ttp−/−) and mice with a conditional overexpression of
human TNFα (ihTNFA), which were additionally defi-
cient in S100a9. Surprisingly, this resulted in a severe
aggravation of inflammation and damage in the joints,
which was attributed to a rescued expression of S100A8/
A8 homodimers due to an inadequate breakdown of
S100A8 by the proteasome [35]. S100A8/A8 homodi-
mers lack the ability to tetramerize and therefore stay in
a pro-inflammatory active state [35].
In the present study, we used Il1rn−/− mice that lack
the IL-1RA protein, which competitively blocks the
binding of IL-1β to IL-1RI and thereby decreases IL-1
signaling [24]. Therefore, this mouse strain is often used
as a model to study high IL-1 signaling [25]. Using im-
munohistochemical analysis, we confirmed that neither
S100a9−/− nor Il1rn−/−XS100a9−/− mice showed S100A9
protein expression, whereas profound expression was
observed in Il1rn−/− mice (Additional file 5A). Neverthe-
less, in contrast to the earlier findings under circum-
stances of high TNFα, no rescue of S100A8 expression
could be observed in the inflamed synovium of the ankle
joints of Il1rn−/−XS100a9−/−, although it was clearly vis-
ible within the bone marrow, suggesting that, differently
from TNFα, excessive IL1 signaling does not lead to ac-
cumulation of the S100A8 homodimer in inflammatory
cells in the periphery. As expected, numerous S100A8-
positive cells were present in the synovium and in the
bone marrow of Il1rn−/− mice (Additional file 5B). Eluci-
dating the mechanisms underlying the discrepancy be-
tween these studies requires further investigation to
reveal the complex interaction of TNFα, IL-1, and
S100A8/A9 during RA, although it should be mentioned
that the involvement of S100A8/A9 in these studies was
investigated under very high TNFα and IL-1 signaling.
We did on the other hand, however, also not observe
an amelioration of the pathology in the absence of
S100a9 as might be expected in the absence of a strong
pro-inflammatory factor that has been shown to be in-
volved in many experimental arthritis models. This
could be the result of an already optimal activation of
the IL-1 signaling in the absence of its natural regulator
IL-1RA, which is sufficient to induce the joint pathology
as seen in the Il1rn−/− mice. TLR4, which is the most
dominant receptor for S100A8/A9, and the IL-1β
(See figure on previous page.)
Fig. 3 The absence of S100A9 affects the composition of myeloid populations in the spleen of Il1rn−/− mice. Total cell counts in the bone
marrow were significantly higher in mice deficient in Il1rn, but not different between Il1rn−/− and Il1rn−/−XS100a9−/− mice. Flow cytometry
analysis showed that the number of CD11b+Ly6Ghigh neutrophils, pro-inflammatory CD11b+Ly6G−Ly6Chigh monocytes and the more
immunomodulatory CD11b+Ly6G−Ly6Clow monocytes, and CD11bneg/lowLy6G−Ly6Chigh osteoclast progenitors were significantly increased in the
absence of Il1rn. However, no significant differences were observed for any of these populations between Il1rn−/−XS100a9−/− and Il1rn−/− mice
(A). In contrast to the bone marrow, total cell numbers were not increased in the spleen of Il1rn-deficient mouse strains. Additionally, an
interaction between the absence of Il1rn and S100a9 was present for the numbers of neutrophils and Ly6Chigh monocytes but not for the Ly6Clow
monocytes (B). Scatterplots are shown, with horizontal and vertical lines representing mean ± SEM values. *P < 0.05, **P < 0.01, ***P < 0.001.
Results of the two-way ANOVA with interaction are presented in the table
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Fig. 4 (See legend on next page.)
Di Ceglie et al. Arthritis Research & Therapy          (2021) 23:216 Page 9 of 12
(See figure on previous page.)
Fig. 4 Il1rn−/−XS100a9−/− and Il1rn−/− osteoclast precursors have a comparable osteoclastogenic potential in vitro. Photomicrographs of tartrate-
resistant acid phosphatase staining of in vitro differentiated osteoclasts derived from bone marrow cells of wild type (WT), S100a9−/−, Il1rn−/−, and
Il1rn−/−XS100a9−/− mice (A, original magnification ×40). Quantification showed an increased formation of big (6 or more nuclei) osteoclasts in
Il1rn-deficient strains compared to S100a9−/− and WT control cells. No differences were present between Il1rn−/− and Il1rn−/−XS100a9−/− cells (B).
Scatterplots are shown, with horizontal and vertical lines representing mean ± SEM values. *P < 0.01. Results of the two-way ANOVA with
interaction are presented in the table
Fig. 5 The absence of S100A9 does not ameliorate cartilage and bone erosion in 20-week-old Il1rn−/− mice. Representative photomicrographs of
Safranin-O/Fast Green-stained sections showing cartilage and bone erosion in the ankle joints of 20-week-old S100a9−/−, Il1rn−/−, and
Il1rn−/−XS100a9−/− mice (A, original magnification ×200 and B, original magnification ×100). Quantification of cartilage erosion at the tibia,
proximal and distal sides of the talus, and proximal side of the navicular bone with an arbitrary score showed no significant differences between
Il1rn−/−XS100a9−/− and Il1rn−/− mice (C). No significant differences in bone erosion were observed between Il1rn−/−XS100a9−/− and Il1rn−/− mice as
quantified at 8 locations along the tibia, talus, and navicular bone (D). Scatterplots are shown, with horizontal and vertical lines representing
mean ± SEM values. Each data point represents the sum score of the right and left ankle joints of one mouse. ns not significant, ***P < 0.001
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receptor IL-1R1 both activate the MyD88, IRAK, TRAF6
signaling pathway, and in this model, only IL-1 signaling
in the absence of its natural inhibitor might already be
sufficient to activate this intracellular signaling pathway
to such an extent that the disease pathology progresses
[36]. In agreement with this idea, it has been shown that
the TLR4 ligand lipopolysachariden (LPS) is able to re-
store the development of K/BxN serum transfer arthritis
in Il1r1−/− mice, which were protected from the develop-
ment of pathology in the absence of LPS [37]. A possible
second mechanism to explain our findings is that, like
S100A8/A9, other factors that are present during arth-
ritis development can induce IL-1β expression and regu-
late its activation and as such be sufficient to fully
activate IL-1β in Il1rn−/−XS100a9−/− mice [38–41].
Conclusion
In conclusion, our data further underline the model-
specific effects of the alarmin S100A8/A9 and show that
although S100A8/A9 is a good biomarker for the devel-
opment of inflammation and cartilage and bone damage,
it is not crucially involved in these processes in Il1rn−/−
mice.
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